Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1GUSELKUMAB
(Tremfya (TN))		[1] Guselkumab (Tremfya)[1] Guselkumab (Tremfya (TN)) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[5] 37, 41, 51, 96, 97 💬
2Guselkumab 100 mg
(Tremfya (TN))		[1] Guselkumab (Tremfya)[1] Guselkumab (Tremfya (TN)) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[1] 37 💬
3Guselkumab Dose 1
(Tremfya (TN))		[1] Guselkumab (Tremfya)[1] Guselkumab (Tremfya (TN)) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[3] 51, 96, 97 💬
4Guselkumab Dose 2
(Tremfya (TN))		[1] Guselkumab (Tremfya)[1] Guselkumab (Tremfya (TN)) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[3] 51, 96, 97 💬
5Guselkumab Dose 3
(Tremfya (TN))		[1] Guselkumab (Tremfya)[1] Guselkumab (Tremfya (TN)) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[2] 96, 97 💬
6Guselkumab Dose 4
(Tremfya (TN))		[1] Guselkumab (Tremfya)[1] Guselkumab (Tremfya (TN)) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[1] 96 💬
7Guselkumab Dose 5
(Tremfya (TN))		[1] Guselkumab (Tremfya)[1] Guselkumab (Tremfya (TN)) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[1] 96 💬
8TREMFYA[1] Guselkumab (Tremfya)[1] Guselkumab (Tremfya (TN)) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[2] 37, 97 💬
9TREMFYA®[1] Guselkumab (Tremfya)[1] Guselkumab (Tremfya (TN)) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[2] 37, 97 💬